Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The MAX study: Mitomycin C, Avastin and Xeloda in untreated metastatic colorectal cancer
2005-005761-11Phase 2Completed
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Mar 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of bevacizumab, capecitabine and mitomycin c in metastatic colon cancer (mCRC), sponsored by Australasian Gastro-Intestinal Trials Group. Primary endpoint: Phase II primary endpoint. Started Mar 2006; status: completed.
02
Drugs
bevacizumabcapecitabinemitomycin c
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2005-005761-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005761-11.